Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART TWO)
Questions
1. Could you give us an overview of the mechanisms of chimeric antigen receptor (CAR) T-cell resistance? 00:15-05:28
2. What strategies are being explored to prevent and treat CAR-T cell resistance? 05:28-09:16
Speaker Disclosure: Marco Ruella discloses research support from Abclon, nanoString and Beckman-Coulter; advisory board membership from Abclon, Bayer, CART Tech, UPenn (partly licensed to Novartis), Tmunity, viTToria biotherapeutics, GSK and Sana; consultancy from nanoString and BMS and is the scientific founder of viTToria biotherapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
